Clinical outcomes and risk factor of immune checkpoint inhibitors-related pneumonitis in non-small cell lung cancer patients with chronic obstructive pulmonary disease
Abstract Objectives: Chronic obstructive pulmonary disease (COPD) is the most common co-morbidity associated with non-small cell lung cancer (NSCLC) patients. Immune checkpoint inhibitors related pneumonitis (CIP) is a common immune-related adverse event that can be life-threatening. The study aims...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-12-01
|
| Series: | BMC Pulmonary Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12890-022-02190-w |
| _version_ | 1797985437377101824 |
|---|---|
| author | Zhu Zeng Jingjing Qu Yake Yao Fei Xu Shan Lu Pei Zhang Yinan Yao Ning Li Jianying Zhou Yuehong Wang |
| author_facet | Zhu Zeng Jingjing Qu Yake Yao Fei Xu Shan Lu Pei Zhang Yinan Yao Ning Li Jianying Zhou Yuehong Wang |
| author_sort | Zhu Zeng |
| collection | DOAJ |
| description | Abstract Objectives: Chronic obstructive pulmonary disease (COPD) is the most common co-morbidity associated with non-small cell lung cancer (NSCLC) patients. Immune checkpoint inhibitors related pneumonitis (CIP) is a common immune-related adverse event that can be life-threatening. The study aims to evaluate the association of COPD with the incidence and outcome of CIP in NSCLC patients receiving immune checkpoint inhibitors (ICIs). Materials and methods: We retrospectively collected data from 122 patients diagnosed with NSCLC and treated with ICIs in our department. Baseline pulmonary function was performed in the whole cohort. The incidence, risk factors, treatment and outcome of CIP patients were evaluated. Furthermore, the efficacy of ICIs in patients with COPD was analyzed. Results: Nineteen patients (15.5%, 19/122) developed CIP during ICIs treatment, most patients with CIP were grade 1–2, and the incidence of CIP was comparable in patients with COPD and those without COPD (18.0% vs. 13.1%, P = 0.618). In addition, an increasing trend in the incidence of CIP among patients with pulmonary fibrosis on baseline chest CT scans (27.3% vs. 13.0%, P = 0.093). There is a longer progression-free survival in COPD patients than the non-COPD patients. Conclusion: Coexisting COPD did not predict the higher risk of CIP in NSCLC treated with ICIs therapy. Nevertheless, pre-existing pulmonary fibrosis on CT scan may increase the risk of CIP, close monitoring is advised in these patients during ICIs. |
| first_indexed | 2024-04-11T07:18:08Z |
| format | Article |
| id | doaj.art-bfbde4ccaec74701827e5d5b9ae41543 |
| institution | Directory Open Access Journal |
| issn | 1471-2466 |
| language | English |
| last_indexed | 2024-04-11T07:18:08Z |
| publishDate | 2022-12-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Pulmonary Medicine |
| spelling | doaj.art-bfbde4ccaec74701827e5d5b9ae415432022-12-22T04:37:52ZengBMCBMC Pulmonary Medicine1471-24662022-12-0122111110.1186/s12890-022-02190-wClinical outcomes and risk factor of immune checkpoint inhibitors-related pneumonitis in non-small cell lung cancer patients with chronic obstructive pulmonary diseaseZhu Zeng0Jingjing Qu1Yake Yao2Fei Xu3Shan Lu4Pei Zhang5Yinan Yao6Ning Li7Jianying Zhou8Yuehong Wang9Department of Respiratory Diseases, Thoracic Disease Center, The First Affiliated Hospital, Zhejiang University School of MedicineDepartment of Respiratory Diseases, Thoracic Disease Center, The First Affiliated Hospital, Zhejiang University School of MedicineDepartment of Respiratory Diseases, Thoracic Disease Center, The First Affiliated Hospital, Zhejiang University School of MedicineDepartment of Respiratory Diseases, Thoracic Disease Center, The First Affiliated Hospital, Zhejiang University School of MedicineDepartment of Respiratory Diseases, Thoracic Disease Center, The First Affiliated Hospital, Zhejiang University School of MedicineDepartment of Respiratory Diseases, Thoracic Disease Center, The First Affiliated Hospital, Zhejiang University School of MedicineDepartment of Respiratory Diseases, Thoracic Disease Center, The First Affiliated Hospital, Zhejiang University School of MedicineDepartment of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of MedicineDepartment of Respiratory Diseases, Thoracic Disease Center, The First Affiliated Hospital, Zhejiang University School of MedicineDepartment of Respiratory Diseases, Thoracic Disease Center, The First Affiliated Hospital, Zhejiang University School of MedicineAbstract Objectives: Chronic obstructive pulmonary disease (COPD) is the most common co-morbidity associated with non-small cell lung cancer (NSCLC) patients. Immune checkpoint inhibitors related pneumonitis (CIP) is a common immune-related adverse event that can be life-threatening. The study aims to evaluate the association of COPD with the incidence and outcome of CIP in NSCLC patients receiving immune checkpoint inhibitors (ICIs). Materials and methods: We retrospectively collected data from 122 patients diagnosed with NSCLC and treated with ICIs in our department. Baseline pulmonary function was performed in the whole cohort. The incidence, risk factors, treatment and outcome of CIP patients were evaluated. Furthermore, the efficacy of ICIs in patients with COPD was analyzed. Results: Nineteen patients (15.5%, 19/122) developed CIP during ICIs treatment, most patients with CIP were grade 1–2, and the incidence of CIP was comparable in patients with COPD and those without COPD (18.0% vs. 13.1%, P = 0.618). In addition, an increasing trend in the incidence of CIP among patients with pulmonary fibrosis on baseline chest CT scans (27.3% vs. 13.0%, P = 0.093). There is a longer progression-free survival in COPD patients than the non-COPD patients. Conclusion: Coexisting COPD did not predict the higher risk of CIP in NSCLC treated with ICIs therapy. Nevertheless, pre-existing pulmonary fibrosis on CT scan may increase the risk of CIP, close monitoring is advised in these patients during ICIs.https://doi.org/10.1186/s12890-022-02190-wCheckpoint inhibitors related pneumonitisChronic obstructive pulmonary diseaseImmune-related adverse eventsImmune checkpoint inhibitorsLung cancer |
| spellingShingle | Zhu Zeng Jingjing Qu Yake Yao Fei Xu Shan Lu Pei Zhang Yinan Yao Ning Li Jianying Zhou Yuehong Wang Clinical outcomes and risk factor of immune checkpoint inhibitors-related pneumonitis in non-small cell lung cancer patients with chronic obstructive pulmonary disease BMC Pulmonary Medicine Checkpoint inhibitors related pneumonitis Chronic obstructive pulmonary disease Immune-related adverse events Immune checkpoint inhibitors Lung cancer |
| title | Clinical outcomes and risk factor of immune checkpoint inhibitors-related pneumonitis in non-small cell lung cancer patients with chronic obstructive pulmonary disease |
| title_full | Clinical outcomes and risk factor of immune checkpoint inhibitors-related pneumonitis in non-small cell lung cancer patients with chronic obstructive pulmonary disease |
| title_fullStr | Clinical outcomes and risk factor of immune checkpoint inhibitors-related pneumonitis in non-small cell lung cancer patients with chronic obstructive pulmonary disease |
| title_full_unstemmed | Clinical outcomes and risk factor of immune checkpoint inhibitors-related pneumonitis in non-small cell lung cancer patients with chronic obstructive pulmonary disease |
| title_short | Clinical outcomes and risk factor of immune checkpoint inhibitors-related pneumonitis in non-small cell lung cancer patients with chronic obstructive pulmonary disease |
| title_sort | clinical outcomes and risk factor of immune checkpoint inhibitors related pneumonitis in non small cell lung cancer patients with chronic obstructive pulmonary disease |
| topic | Checkpoint inhibitors related pneumonitis Chronic obstructive pulmonary disease Immune-related adverse events Immune checkpoint inhibitors Lung cancer |
| url | https://doi.org/10.1186/s12890-022-02190-w |
| work_keys_str_mv | AT zhuzeng clinicaloutcomesandriskfactorofimmunecheckpointinhibitorsrelatedpneumonitisinnonsmallcelllungcancerpatientswithchronicobstructivepulmonarydisease AT jingjingqu clinicaloutcomesandriskfactorofimmunecheckpointinhibitorsrelatedpneumonitisinnonsmallcelllungcancerpatientswithchronicobstructivepulmonarydisease AT yakeyao clinicaloutcomesandriskfactorofimmunecheckpointinhibitorsrelatedpneumonitisinnonsmallcelllungcancerpatientswithchronicobstructivepulmonarydisease AT feixu clinicaloutcomesandriskfactorofimmunecheckpointinhibitorsrelatedpneumonitisinnonsmallcelllungcancerpatientswithchronicobstructivepulmonarydisease AT shanlu clinicaloutcomesandriskfactorofimmunecheckpointinhibitorsrelatedpneumonitisinnonsmallcelllungcancerpatientswithchronicobstructivepulmonarydisease AT peizhang clinicaloutcomesandriskfactorofimmunecheckpointinhibitorsrelatedpneumonitisinnonsmallcelllungcancerpatientswithchronicobstructivepulmonarydisease AT yinanyao clinicaloutcomesandriskfactorofimmunecheckpointinhibitorsrelatedpneumonitisinnonsmallcelllungcancerpatientswithchronicobstructivepulmonarydisease AT ningli clinicaloutcomesandriskfactorofimmunecheckpointinhibitorsrelatedpneumonitisinnonsmallcelllungcancerpatientswithchronicobstructivepulmonarydisease AT jianyingzhou clinicaloutcomesandriskfactorofimmunecheckpointinhibitorsrelatedpneumonitisinnonsmallcelllungcancerpatientswithchronicobstructivepulmonarydisease AT yuehongwang clinicaloutcomesandriskfactorofimmunecheckpointinhibitorsrelatedpneumonitisinnonsmallcelllungcancerpatientswithchronicobstructivepulmonarydisease |